Back to search
FDAFDA · Food and drugs·Recall number D-0003-2024

ePHEDrine in 0.9% sodium chloride, 50 mg/5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1

Published October 11, 2023 · Recall initiated: September 21, 2023

Summary

FDA records drug Class II recall D-0003-2024, published October 11, 2023 and initiated September 21, 2023. Recalling firm: Central Admixture Pharmacy Services Inc; Status: Terminated; Reported quantity: 1,590 5 mL Syringes.; Lot: Lot: 17-275252, 17-275276, Exp. 10/2/2023; 17-275525, Exp. 10/5/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility:

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Central Admixture Pharmacy Services Inc
Distributor
Nationwide in the USA
Lot
Lot: 17-275252, 17-275276, Exp. 10/2/2023; 17-275525, Exp. 10/5/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ePHEDrine in 0.9% sodium chloride, 50 mg/5 mL, (10 mg/mL), 5 mL Syringe, Rx only, CAPS Inc., Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-6004-1 recalled?

Yes. FDA published recall D-0003-2024 on October 11, 2023. Reported hazard: Lack of assurance of sterility:

What should I do if I have this product?

Voluntary: Firm initiated · Letter